Eli Lilly to connect its upcoming digital insulin pen with Welldoc's diabetes app

"Eli Lilly & Co. has signed a deal to link Welldoc’s digital health platform with its upcoming connected insulin devices and therapies.
The two will collaborate on a new version of Welldoc’s long-running BlueStar diabetes management app, to include dosing data for several insulins produced by Lilly, ahead of the Big Pharma’s future launch of its connected insulin pen.
The BlueStar app has been cleared by the FDA for adults with Type 1 or Type 2 diabetes, offering insulin titration support, a bolus calculator and personalized health coaching. It is designed to integrate with a range of blood sugar readers and continuous glucose monitoring systems.
The app received its eighth agency green light last June, expanding its use to people using long-acting insulins. More recently, Welldoc submitted a review request for its ninth indication, with the goal of adding bolus and premixed insulin titration support in type 2 diabetes.
Meanwhile, the initial version of Lilly’s digital insulin pen will include an electronic module that attaches to the top of a prefilled, disposable delivery device which will pair with the app to keep track of its usage. The company is also developing a fully disposable pen..." Lire la suite